PMID- 11325842
OWN - NLM
STAT- MEDLINE
DCOM- 20010521
LR  - 20071114
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 61
IP  - 9
DP  - 2001 May 1
TI  - Targeting dendritic cells to enhance DNA vaccine potency.
PG  - 3704-11
AB  - DNA vaccination that can induce both cellular and humoral immune responses has 
      become an attractive immunization strategy against cancer and infection. 
      Dendritic cells (DCs) play a critical role in the induction of immune responses 
      by DNA vaccination. However, a major problem of DNA vaccination is its limited 
      potency, because only a very limited fraction of injected DNA molecules are taken 
      up by DCS: In this study, we describe a novel DNA vaccination strategy to enhance 
      uptake and presentation of antigens by DCS: Specifically, we developed a DNA 
      vaccine based upon expression of a model hepatitis B virus (HBV) e antigen fused 
      to an IgG Fc fragment. After vaccination, the DNA are taken up by cells that 
      produce and secrete the antigen-Fc fusion proteins. The secreted fusion proteins, 
      in addition to inducing B cells, are efficiently captured and processed by DCs 
      via receptor-mediated endocytosis and then presented to the MHC class II and as 
      -I (cross-priming). The results of this study demonstrate that broad enhancement 
      of antigen-specific CD4+ helper, CD8+ cytotoxic T-cell, and B-cell responses can 
      be achieved by this DNA vaccination strategy. Thus, the strategy capable of 
      inducing all arms of the adaptive immunity may provide a novel, generic design 
      for the development of therapeutic and preventive DNA vaccines.
FAU - You, Z
AU  - You Z
AD  - Center for Cell and Gene Therapy, Departments of Molecular and Human Genetics, 
      Baylor College of Medicine, Houston, Texas 77030, USA.
FAU - Huang, X
AU  - Huang X
FAU - Hester, J
AU  - Hester J
FAU - Toh, H C
AU  - Toh HC
FAU - Chen, S Y
AU  - Chen SY
LA  - eng
GR  - AI41959/AI/NIAID NIH HHS/United States
GR  - RR13272/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Hepatitis B e Antigens)
RN  - 0 (Immunoglobulin Fragments)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, IgG)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vaccines, DNA)
SB  - IM
MH  - Animals
MH  - Antibody Formation/immunology
MH  - Antigen Presentation/immunology
MH  - B-Lymphocytes/immunology
MH  - Coculture Techniques
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Hepatitis B e Antigens/genetics/immunology
MH  - Immunoglobulin Fragments/genetics/immunology
MH  - Immunoglobulin G/genetics/immunology
MH  - Immunotherapy, Active/*methods
MH  - Immunotherapy, Adoptive/*methods
MH  - Lymphocyte Activation/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Receptors, IgG/genetics/immunology
MH  - Recombinant Fusion Proteins/genetics/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Th1 Cells/immunology
MH  - Vaccines, DNA/*immunology
EDAT- 2001/04/28 10:00
MHDA- 2001/05/25 10:01
CRDT- 2001/04/28 10:00
PHST- 2001/04/28 10:00 [pubmed]
PHST- 2001/05/25 10:01 [medline]
PHST- 2001/04/28 10:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2001 May 1;61(9):3704-11.